PROCEPT BioRobotics (PRCT) Current Deferred Revenue (2020 - 2026)

PROCEPT BioRobotics (PRCT) has 7 years of Current Deferred Revenue data on file, last reported at $13.7 million in Q1 2026.

• On a quarterly basis, Current Deferred Revenue rose 39.83% year-over-year to $13.7 million in Q1 2026; TTM through Mar 2026 was $13.7 million, a 39.83% increase from a year earlier, with the FY2025 full-year figure at $13.0 million, up 36.41% from the prior year.
• Current Deferred Revenue for Q1 2026 stood at $13.7 million, up from $13.0 million in the prior quarter.
• Over the last five years, Current Deferred Revenue for PRCT reached as high as $13.7 million in Q1 2026 and fell as low as $1.4 million in Q1 2022.
• Historically, Current Deferred Revenue has averaged $6.8 million across 5 years, with a median of $5.9 million in 2024.
• Across the five-year window, Current Deferred Revenue jumped 188.23% in 2023 and soared 33.5% in 2025, its largest moves.
• Year by year, Current Deferred Revenue stood at $2.9 million in 2022, then surged by 98.11% to $5.7 million in 2023, then surged by 69.11% to $9.6 million in 2024, then jumped by 36.41% to $13.0 million in 2025, then rose by 5.01% to $13.7 million in 2026.
• Per Business Quant data, the three most recent Current Deferred Revenue figures were $13.7 million in Q1 2026, $13.0 million in Q4 2025, and $10.7 million in Q3 2025.